Program
treprostinil
Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.
Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeutics | 625 open or running | phase 4since Apr 14, 2003 | Oct 18, 1999 | Nov 2027phase 3 · NCT05943535 |
| Liquidia Technologiesits history only | 64 open or running | phase 4since Aug 7, 2026 | Jan 3, 2018 | Feb 2027phase 2 · NCT07748000 |
| Mannkindits history only | 10 open or running | phase 1since Mar 1, 2018 | Mar 1, 2018 | none ahead |
| Pharmosa Biopharmits history only | 10 open or running | phase 1since Jul 23, 2019 | Jul 23, 2019 | none ahead |
| SciPharm SàRLits history only | 10 open or running | phase 3since Aug 12, 2011 | Aug 12, 2011 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of United Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 44 studies since May 19, 2003.
- Jan 6, 2017Phase 2 study in Pulmonary Arterial HypertensionNCT03016468
- Jan 27, 20173 phase 3 studiesNCT03055234, NCT03037580, NCT03043651
- Feb 9, 2017Phase 4 study in Pulmonary Arterial HypertensionNCT03055221 · 20 enrolled
- Mar 20, 2018Phase 4 study in Pulmonary Arterial HypertensionNCT03497689 · 36 enrolled · United States
- Mar 29, 2018Phase 3 study in Hypertension, PulmonaryNCT03496623 · 188 enrolled · United States, Argentina, Israel and more
- Jan 2, 2019Phase 3 study in Hypertension, PulmonaryNCT03794583 · 41 enrolled · United States, Israel, Italy
- May 9, 2019Phase 1 study in Pulmonary Arterial HypertensionNCT03950739 · 51 enrolled · United States
- Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121
- Jan 12, 2021Phase 3 study in Idiopathic Pulmonary FibrosisNCT04708782 · 598 enrolled · United States, Canada, Chile
- May 20, 2021Phase 3 study in Idiopathic Pulmonary FibrosisNCT04905693 · 1,850 planned · United States, Argentina, Australia and more
- Jan 10, 2022Phase 4 study in Pulmonary Arterial HypertensionNCT05203510 · 52 enrolled · United States
- Feb 15, 2022Phase 3 study in Idiopathic Pulmonary FibrosisNCT05255991 · 597 enrolled · Argentina, Australia, Belgium and more
- Jul 5, 2023Phase 3 study in Lung Diseases, InterstitialNCT05943535 · 698 planned · United States, Argentina, Australia and more
- Oct 19, 2026Phase 2 study in Hypertension, PulmonaryNCT07923591 · 40 planned · United States
- Oct 19, 2026Phase 3 study in Hypertension, PulmonaryNCT07923526 · 400 planned · United States
Ahead
- Nov 2027Primary completion: phase 3 study in Lung Diseases, InterstitialNCT05943535
- May 2028Primary completion: phase 2 study in Hypertension, PulmonaryNCT07923591
- Dec 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT04905693
- Sep 2034Primary completion: phase 3 study in Hypertension, PulmonaryNCT07923526
TargetBeta
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selexipagrule | Johnson & Johnson | phase 4 | 23 |
Studies
The newest 60 of 62 United Therapeutics leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923591Hypertension, Pulmonary · United States | 2 | Not yet recruiting | May 2028 | 40 |
| NCT07923526Hypertension, Pulmonary · United States | 3 | Not yet recruiting | Sep 2034 | 400 |
| NCT05943535Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Nov 2027 | 698 |
| NCT05255991Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more | 3 | Completed | Jun 30, 2025 | 597 |
| NCT05203510Pulmonary Arterial Hypertension · United States | 4 | Active, not recruiting | Apr 30, 2026 | 52 |
| NCT04905693Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | By invitation | Dec 2029 | 1,850 |
| NCT04708782Idiopathic Pulmonary Fibrosis · United States, Canada, Chile | 3 | Completed | Feb 2, 2026 | 598 |
| NCT03950739Pulmonary Arterial Hypertension · United States | 1 | Completed | Aug 22, 2023 | 51 |
| NCT03794583Hypertension, Pulmonary · United States, Israel, Italy | 3 | Terminated | Nov 29, 2022 | 41 |
| NCT03496623Hypertension, Pulmonary · United States, Argentina, Israel and more | 3 | Terminated | Oct 13, 2022 | 188 |
| NCT03497689Pulmonary Arterial Hypertension · United States | 4 | Completed | May 11, 2022 | 36 |
| NCT03055221Pulmonary Arterial Hypertension | 4 | Completed | Feb 25, 2014 | 20 |
| NCT03043651Hypertension, Pulmonary · United States | 3 | Terminated | Mar 2, 2020 | 48 |
| NCT03055234Pulmonary Hypertension Associated With Sickle Cell Disease | 3 | Withdrawn | Dec 2021 | 0 |
| NCT03037580Hypertension, Pulmonary · United States | 3 | Terminated | Dec 3, 2019 | 84 |
| NCT03016468Pulmonary Arterial Hypertension | 2 | Withdrawn | Sep 2018 | 0 |
| NCT03012646Hypertension, Pulmonary | 2 | Withdrawn | Apr 2019 | 0 |
| NCT02999906Pulmonary Arterial Hypertension | 3 | Withdrawn | Dec 2021 | 0 |
| NCT02893995Pulmonary Arterial Hypertension · China | 4 | Withdrawn | Apr 2018 | 0 |
| NCT02882126Pulmonary Arterial Hypertension · China | 4 | Withdrawn | Jun 2021 | 0 |
| NCT02847260Pulmonary Arterial Hypertension | 4 | Completed | Mar 2014 | 39 |
| NCT02633293Hypertension, Pulmonary · United States, Puerto Rico | 3 | Terminated | Aug 1, 2021 | 243 |
| NCT02630316Hypertension, Pulmonary · United States, Puerto Rico | 3 | Completed | Dec 26, 2019 | 326 |
| NCT02603068Hypertension, Pulmonary · United States | 2 | Withdrawn | Apr 2018 | 0 |
| NCT02276872PAH · United States | 2 | Completed | Jul 20, 2017 | 32 |
| NCT02318758Healthy · United States | 1 | Completed | Oct 2014 | 32 |
| NCT02261883Persistent Fetal Circulation Syndrome · United States | 2 | Terminated | Sep 27, 2022 | 42 |
| NCT01934582Pulmonary Arterial Hypertension · United States | 3 | Completed | Nov 2013 | 13 |
| NCT01884038Reperfusion Injury · United States | 3 | Withdrawn | Jun 2010 | 0 |
| NCT01746485Healthy · United States | 1 | Completed | Jul 2012 | 19 |
| NCT01557660Pulmonary Arterial Hypertension | 3 | Withdrawn | Dec 2018 | 0 |
| NCT01557647Pulmonary Arterial Hypertension | 3 | Withdrawn | Dec 2015 | 0 |
| NCT01560637Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Aug 12, 2021 | 471 |
| NCT01560624Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Jun 24, 2018 | 690 |
| NCT01588405Pulmonary Arterial Hypertension · United States | 2 | Completed | Jul 2014 | 33 |
| NCT01477333Pulmonary Arterial Hypertension · United States | 2 | Completed | Nov 2013 | 18 |
| NCT01172496Pulmonary Arterial Hypertension · United States | 1 | Completed | Aug 2010 | 24 |
| NCT01165476Pulmonary Arterial Hypertension · United States | 1 | Completed | Aug 2010 | 64 |
| NCT01153386Pulmonary Arterial Hypertension · United States | 1 | Completed | Aug 2010 | 36 |
| NCT01131845Pulmonary Arterial Hypertension · United States | 1 | Completed | Sep 2010 | 16 |
| NCT01104870Hypertension, Pulmonary · United States | 2 | Completed | Jan 2013 | 50 |
| NCT01027949Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 3 | Completed | Feb 12, 2020 | 894 |
| NCT00963027Hypertension, Pulmonary · United States | 1 | Completed | Oct 2009 | 30 |
| NCT00963001Hypertension, Pulmonary · United States | 1 | Completed | Nov 2009 | 32 |
| NCT00887978Hypertension, Pulmonary · United States, Belgium, Canada and more | 3 | Completed | Jul 2011 | 310 |
| NCT00848939Scleroderma, Systemic · United States | 1 | Completed | Jan 2010 | 28 |
| NCT00848107Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Terminated | Sep 2011 | 115 |
| NCT00775463Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Completed | Mar 2011 | 148 |
| NCT00760916Hypertension, Pulmonary · United States, Australia, Mexico | 3 | Withdrawn | Jan 2009 | 0 |
| NCT00741819Pulmonary Arterial Hypertension · United States | 4 | Completed | Mar 2010 | 73 |
| NCT00643604Hypertension, Pulmonary · United States | 4 | Terminated | Jan 2010 | 7 |
| NCT00494533Pulmonary Arterial Hypertension · India | 4 | Terminated | Oct 2005 | 45 |
| NCT00458042Hypertension, Pulmonary · United States | 4 | Terminated | 10 | |
| NCT00439946Pulmonary Arterial Hypertension · United States | 4 | Terminated | Sep 2009 | 8 |
| NCT00373360Hypertension, Pulmonary · United States | 4 | Completed | Jan 2008 | 10 |
| NCT00325442Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Completed | Sep 2008 | 354 |
| NCT00325403Hypertension, Pulmonary · United States, Austria, Belgium and more | 3 | Completed | Apr 2011 | 349 |
| NCT00147199Hypertension, Pulmonary · United States, Austria, Belgium and more | 3 | Completed | Oct 2007 | 235 |
| NCT00067041Peripheral Vascular Diseases · United States | 3 | Terminated | Dec 2003 | 30 |
| NCT00060996Chronic Limb-Threatening Ischemia · United States | 3 | Terminated | Sep 2004 | 30 |
How it is read
Names in the registry
- “Inhaled Treprostinil”, 7 entries
- “treprostinil diethanolamine”, 6 entries
- “Oral Treprostinil”, 5 entries
- “treprostinil sodium”, 5 entries
- “UT-15C SR”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 38 studies
- Hypertension, Pulmonary, 17 studies
- Scleroderma, Systemic, 4 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Chronic Limb-Threatening Ischemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.